EVAX

Evaxion Biotech AS (EVAX)

Evaxion Biotech AS

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:EVAX

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/15	22 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2025/01/15	22 : 00	GlobeNewswire Inc.	Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01	NASDAQ:EVAX	Evaxion Biotech AS
2025/01/15	06 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2025/01/15	06 : 05	GlobeNewswire Inc.	Evaxion announces completion of ADS ratio change	NASDAQ:EVAX	Evaxion Biotech AS
2025/01/10	22 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2025/01/10	22 : 00	GlobeNewswire Inc.	Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change	NASDAQ:EVAX	Evaxion Biotech AS
2025/01/07	23 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/30	22 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/30	22 : 00	GlobeNewswire Inc.	Evaxion announces plan to implement ADS ratio change	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/27	06 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/18	07 : 09	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/17	22 : 16	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/17	22 : 00	GlobeNewswire Inc.	Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/12	22 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/12	22 : 00	GlobeNewswire Inc.	Evaxion establishes new AI-derived precision cancer vaccine concept	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/09	23 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/09	22 : 00	GlobeNewswire Inc.	Evaxion announces 2025 milestones reflecting continued strong strategy execution	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/06	06 : 53	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/03	20 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/12/02	22 : 00	GlobeNewswire Inc.	Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress	NASDAQ:EVAX	Evaxion Biotech AS
2024/11/19	06 : 30	Edgar (US Regulatory)	Form F-1 - Registration statement for certain foreign private issuers	NASDAQ:EVAX	Evaxion Biotech AS
2024/11/13	23 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/11/13	22 : 00	GlobeNewswire Inc.	Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing	NASDAQ:EVAX	Evaxion Biotech AS
2024/11/13	21 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/11/13	21 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/11/12	22 : 00	GlobeNewswire Inc.	Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1	NASDAQ:EVAX	Evaxion Biotech AS
2024/10/31	23 : 20	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/10/31	21 : 00	GlobeNewswire Inc.	Evaxion announces business update and third quarter 2024 financial results	NASDAQ:EVAX	Evaxion Biotech AS
2024/10/28	22 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/10/28	21 : 00	GlobeNewswire Inc.	Evaxion to announce business update and third quarter 2024 financial results on October 31	NASDAQ:EVAX	Evaxion Biotech AS